UK markets closed

NIKKEI 225
40,580.76
+506.07(+1.26%)
HANG SENG
17,978.57
+209.43(+1.18%)
CRUDE OIL
83.88
+1.07(+1.29%)
GOLD FUTURES
2,369.40
+36.00(+1.54%)
DOW
39,308.00
-23.85(-0.06%)
Bitcoin GBP
47,051.38
-1,580.38(-3.25%)

What to do with an inheritance

For many, an inheritance represents a once in a lifetime opportunity

ITCI Jan 2025 65.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

14.00

0.00

(0.00%)

At close: 09:56AM EDT

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
The Relative Strength (RS) Rating for Intra-Cellular Therapies stock entered a new percentile Thursday, with a rise from 75 to 87. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.